Study Highlights Long-Term Success of Immunosuppressant-Free Islet Cell Therapy for Type 1 Diabetes

New peer-reviewed data published in NEJM indicates that Sana Biotechnology's experimental islet cell therapy, UP421, shows durable safety and function for 14 months in treating type 1 diabetes. Crucially, this treatment may eliminate the need for immunosuppressive drugs, a major challenge in current transplant therapies. This represents a significant advancement in managing the condition, offering new hope for patients.